MREO: Mereo BioPharma Forward P/E Multiple

Mereo BioPharma (MREO) develops advanced antibodies to combat oncology and restore bone density. The asset's market valuation trend reflects a value of 0.00, which is critical for a business specializing in orphan disease therapies. The company currently relies on external partner funding as its primary drug candidates undergo testing and internal profit generators are temporarily absent.

Mereo BioPharma - MREO Price to Expected Earnings Ratio (period 07/04/2022 - 11/12/2026)

Mereo BioPharma Group PLC (MREO) - metric breakdowns and financial figures

- stock value and consensus price forecast:

Price Chart Mereo BioPharma|MREO - Price Target Chart

- market capitalization information:

Market Capitalization Mereo BioPharma Group|MREO - Company Buyout Price

- book capitalization information:

Accounting Value per Share Mereo BioPharma|MREO - Net Asset Value|Market Capitalization to Book Value Ratio mereobiopharma.com|MREO - Company Assets

- debt and liquidity details:

- financial results and valuation multiples details:

MREO - Net Profit|Expected Profit Mereo BioPharma|MREO - Company Value to Net Income|Future Price to Earnings Mereo BioPharma|MREO - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Mereo BioPharma Group|MREO - Operating profit EBITDA|Earnings per share for the last twelve months Mereo BioPharma|MREO - Net earnings per share for the last 12 months|Quarterly EPS earnings growth mereobiopharma.com|MREO - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Mereo BioPharma

Fundamental valuation:MREO Mereo BioPharma Group plc

The success of Mereo BioPharma (MREO) is driven by the efficiency of orphan drug development and FDA approval. The company's forward P/E ratio compares current market capitalization with expected net income for future periods. The rising values on this chart reflect market confidence in the commercialization of its drugs. A decline in the ratio may signal risks within clinical trials. The indicator's dynamics determine the fair value of the shares amid uncertainty.

Competitor analysis for Mereo BioPharma

Future Price to Earnings Vertex (VRTX)|Future Price to Earnings ALNY (Alnylam Pharmaceuticals, Inc.)|Forward P/E Multiple INSM (Insmed Inc)|Market Cap to Projected Earnings United Therapeutics Inc. (UTHR)|BMRN: Projected Price to Earnings|Price to Expected Earnings Ratio BBIO|BGM: Forward P/E Multiple|Projected Price to Earnings Ratio Cogent Biosciences Inc (COGT)|XERS (Xeris Biopharma Inc) - Forward P/E Multiple|Price to Future Earnings Ratio KROS (Keros Corp)|Projected Price to Earnings ARCT (Arcturus Therapeutics)|ETON (etonpharma.com) - Future Price to Earnings Multiple|Future Price to Earnings Kamada KMDA|FULC (Fulcrum Therapeutics Inc) - Price to Expected Earnings Ratio|Abeona - Forward P/E Multiple|Future Price to Earnings Multiple PLX (Protalix BioTherapeutics, Inc)|PLRX: Forward P/E Multiple|appliedtherapeutics.com (APLT) - Forward P/E Multiple|Future Price to Earnings Rein Therapeutics|GELS: Future Price to Earnings Multiple|Future Price to Earnings Aytu BioPharma, Inc. (AYTU)|Projected Price to Earnings chemomab.com CMMB|Forward P/E Multiple SRXH (SRx Health Solutions)|Forward P/E Multiple Polyrizon Limited PLRZ|AEZS - Future Price to Earnings|Cyclo Therapeutics Inc. (CYTH) - Projected Price to Earnings|INZY: Forward P/E Multiple|Projected Price to Earnings Ratio Reneo Pharmaceuticals, Inc (RPHM)|Future Price to Earnings COSCIENS Biopharma Inc.